Redeye provides an updated view of our investment thesis of Surgical Science following the company posting excellent Q2 numbers. We revise our near-term estimates, particularly on the margin side, while leaving our mid- to long-term estimates largely unchanged. We notch up our Base Case and valuation range.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/